Revlimid And Copaxone Pricing: Five Not-So-Revealing Revelations From The House Reports
Executive Summary
Investigative reports from the House Oversight and Reform Committee recount well-known records of significant price increases for the drugs, the lack of pricing restraints in the US relative to markets abroad, tactics used to protect the drugs from generic competition and the 'return on investment' from manufacturer assistance programs.
You may also be interested in...
In Rx Pricing Debate, House Dems Key On Stock Buybacks To Counter Worries About R&D Spending Cuts
Of the 14 leading biopharma companies, only AstraZeneca and Roche spent more on R&D than on buybacks and dividends over the past five years, the report from the US House Committee on Oversight and Reform shows.
US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches
Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.
US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches
Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.